Quoin Pharmaceuticals (NASDAQ:QNRX – Get a rating) and IRadimed (NASDAQ:IRMD – Get a rating) are both small-cap medical companies, but which business is superior? We’ll compare the two companies based on valuation strength, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.
Valuation and benefits
This table compares the gross revenue, earnings per share (EPS), and valuation of Quoin Pharmaceuticals and IRadimed.
| Gross revenue | Price/sales ratio | Net revenue | Earnings per share | Price/earnings ratio | |
| Quoin Pharmaceuticals | N / A | N / A | -$21.46 million | N / A | N / A |
| Iradimed | $41.81 million | 9.72 | $9.32 million | $0.83 | 38.98 |
IRadimed has higher revenue and profit than Quoin Pharmaceuticals.
Profitability
This table compares the net margins, return on equity and return on assets of Quoin Pharmaceuticals and IRadimed.
| Net margins | Return on equity | return on assets | |
| Quoin Pharmaceuticals | N / A | N / A | -355.59% |
| Iradimed | 23.22% | 15.59% | 13.48% |
Insider and Institutional Ownership
21.7% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 39.9% of IRadimed shares are held by institutional investors. 43.7% of IRadimed shares are held by insiders. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Quoin Pharmaceuticals has a beta of 1.75, which means its stock price is 75% more volatile than the S&P 500. In comparison, IRadimed has a beta of 0.98, which means its stock price is 2% less volatile than the S&P 500.
Analyst Notes
This is a breakdown of recent valuations of Quoin Pharmaceuticals and IRadimed, as provided by MarketBeat.
| Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
| Quoin Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Iradimed | 0 | 0 | 1 | 0 | 3.00 |
Quoin Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 1,045.15%. IRadimed has a consensus target price of $42.00, indicating a potential upside of 29.83%. Given Quoin Pharmaceuticals’ likely higher upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than IRadimed.
Summary
IRadimed beats Quoin Pharmaceuticals on 7 out of 10 factors compared between the two stocks.
Quoin Pharmaceuticals Company Profile (Get a rating)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, is focused on developing therapeutics for rare and orphan diseases. The company’s lead product is QRX003, a topical lotion to treat Netherton’s syndrome. It is also developing QRX004 for the treatment of dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin diseases. The company is based in Ashburn, Virginia.
IRadimed Company Profile (Get a rating)
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. It offers an MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and an MRI-compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, lateral vehicle pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales managers, clinical support representatives and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Get news and reviews for Quoin Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.
